The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

March 31, 2025, and an updated cash runway guidance into 2029; commercial readiness activities ongoing Over 300 patients enrolled in darovasertib and crizotinib registrational 1L HLA-A2-negative MUM ...

IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) ...

The study by Li et al. provides fundamental findings supported by convincing evidence that they defined cellular reprogramming of androgen receptor in neuroendocrine prostate cancer (NEPC). The ...

Zymeworks' financial stability is evident with $76.3 million in revenue in 2024 and a cash runway extending through late 2027 ...

Our SWITCH approach activates CD3/T-cells only when binding to tumor-associated antigens ... as it is highly upregulated in small cell lung cancer and other high-grade neuroendocrine tumors, while not ...

The company is set to enter clinical development in 2025 with this program, which shows effective tumor uptake and safety ... lung cancer and other high-grade neuroendocrine tumors, while not ...

“We’re particularly excited to share data on ZW209, the latest of our oncology nominated IND programs which has demonstrated promising anti-tumor ... the treatment of neuroendocrine neoplasms.

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Highlighted was ZW209, a novel T cell engager targeting DLL3 in small cell lung cancer, which showed promising anti-tumor activity and is expected to enter an IND submission in the first half of 2026.

ZW171 exhibits strong anti-tumor activity in patient derived xenograft (PDX ... is a cell surface protein overexpressed in small cell lung cancer (SCLC) and other neuroendocrine carcinomas that has ...

Scott Clifton found out Liam would be back at the forefront on the long-running soap — with a terminal brain tumor. “That was something that I had worried about for at least the last decade.